Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Dermresearch

Neither a doctor nor a teaching hospital

Research payments

$591,920

124 payments

Through program year 2025, Dermresearch is reported as receiving $591,920 in research payments, across 124 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $29,068 5
2023 Research $13,259 13
2022 Research $12,338 16
2021 Research $23,033 40
2020 Research $215,031 26
2019 Research $299,191 24

Breakdown

Who paid Research payments · program years 2019–2025
  1. Incyte Corporation $353,294 111 payments
  2. Biofrontera Inc. $199,123 6 payments
  3. Vanda Pharmaceuticals Inc. $28,151 4 payments
  4. Novartis Pharmaceuticals Corporation $9,560 1 payment
  5. AbbVie, Inc. $917 1 payment
  6. Bausch Health US, LLC $875 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $257,243 19 payments
  2. A two-arm parallel, open-label phase I study to evaluate the pharmacokinetics of 5-aminolevulinic acid and protoporphyrin IX in human plasma under maximal use conditions after topical application of 3 tubes ofBF-200 ALA10% gel for photodynamic therapy (PDT)in subjects suffering from actinic keratosis $199,123 6 payments
  3. TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $29,050 1 payment
  4. An Open Label Study Evaluating the Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis $28,151 4 payments
  5. TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $25,307 35 payments
  6. TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $19,471 30 payments
  7. A Multicenter Double Blind Randomized Withdrawal Extension Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Long Term Efficacy Safety and Tolerability Up to 2 Years in Subjects With Moderate to Severe Chronic Plaque Type Psoriasis Co $9,560 1 payment
  8. TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $9,114 13 payments
  9. PD effects and predictive biomarkers of JAK/STAT inhibition with ruxolitinib in operable head and neck squamous cell carcinoma-a window of opportunity trial $7,954 10 payments
  10. A Phase 2, Randomized, Dose Ranging, Vehicle Controlled and Triamcinolone 0.1 percent Cream Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults With Atopic Dermatitis $1,875 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record